Back to News
Market Impact: 0.2
UBS Upgrades Ionis Pharmaceuticals to Buy from Neutral
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 15, 2026, UBS upgraded Ionis Pharmaceuticals from Neutral to Buy; the stock had closed at $42.70 on October 14. The article is truncated before providing the next-session closing price, so the post-upgrade share reaction cannot be determined.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
IONS0.55
UBS0.00
More News
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- These tech stocks are a buy ahead of their earnings reports, Bank of America says
- Citi says interest rates may matter more for economy than stock valuations
- AI Selloff Tests Investor Confidence
- Chip Stocks Just Fell 8 Days in a Row, Their Longest Losing Streak Since 2008
- Susan Dell is the one running the Dells’ $10 billion giving operation—and her biggest bets are on kids, health care, and UT Austin
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Track Guidance Changes Across a Coverage List With AI
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?